You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness
|
|---|---|
| Published in |
PLoS Neglected Tropical Diseases, December 2010
|
| DOI | 10.1371/journal.pntd.0000923 |
| Pubmed ID | |
| Authors |
Els Torreele, Bernadette Bourdin Trunz, David Tweats, Marcel Kaiser, Reto Brun, Guy Mazué, Michael A. Bray, Bernard Pécoul |
| Abstract |
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a fatal parasitic disease caused by trypanosomes. Current treatment options for HAT are scarce, toxic, no longer effective, or very difficult to administer, in particular for the advanced, fatal stage of the disease (stage 2, chronic HAT). New safe, effective and easy-to-use treatments are urgently needed. Here it is shown that fexinidazole, a 2-substituted 5-nitroimidazole rediscovered by the Drugs for Neglected Diseases initiative (DNDi) after extensive compound mining efforts of more than 700 new and existing nitroheterocycles, could be a short-course, safe and effective oral treatment curing both acute and chronic HAT and that could be implemented at the primary health care level. To complete the preclinical development and meet the regulatory requirements before initiating human trials, the anti-parasitic properties and the pharmacokinetic, metabolic and toxicological profile of fexinidazole have been assessed. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 296 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 7 | 2% |
| Germany | 1 | <1% |
| Switzerland | 1 | <1% |
| Portugal | 1 | <1% |
| Vietnam | 1 | <1% |
| France | 1 | <1% |
| Egypt | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 282 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 54 | 18% |
| Researcher | 45 | 15% |
| Student > Master | 43 | 15% |
| Student > Bachelor | 32 | 11% |
| Student > Doctoral Student | 17 | 6% |
| Other | 43 | 15% |
| Unknown | 62 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 60 | 20% |
| Agricultural and Biological Sciences | 48 | 16% |
| Biochemistry, Genetics and Molecular Biology | 43 | 15% |
| Medicine and Dentistry | 26 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 24 | 8% |
| Other | 29 | 10% |
| Unknown | 66 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2023.
All research outputs
#980,982
of 25,461,852 outputs
Outputs from PLoS Neglected Tropical Diseases
#549
of 9,402 outputs
Outputs of similar age
#4,440
of 192,668 outputs
Outputs of similar age from PLoS Neglected Tropical Diseases
#3
of 58 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,402 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,668 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.